<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA"/></p>
<p>EyePoint Pharmaceuticals, Inc.（NASDAQ：EYPT）股票在周一的午盘交易中下跌了 6.4%。股价最低跌至 9.96 美元，最后交易价为 10.02 美元。交易中约有 436,621 股股票交易，较平均日交易量 1,101,198 股下降了 60%。该股票上一个收盘价为 10.71 美元。</p>
<h2>分析师评级变动</h2>
<p>EYPT 已成为多份研究报告的主题。Chardan Capital 将 EyePoint Pharmaceuticals 的目标股价从 39.00 美元降至 28.00 美元，并在 5 月 7 日星期二的一份报告中为该股票设定了 “买入” 评级。Robert W. Baird 将 EyePoint Pharmaceuticals 的目标股价从 46.00 美元降至 38.00 美元，并在 5 月 8 日星期三的一份报告中为该股票设定了 “表现优异” 评级。Capital One Financial 在 2 月 16 日星期五的一份报告中重申了对 EyePoint Pharmaceuticals 股票的 “超重” 评级。Mizuho 将 EyePoint Pharmaceuticals 的目标股价从 39.00 美元降至 30.00 美元，并在 5 月 7 日星期二的一份报告中为该股票设定了 “买入” 评级。最后，StockNews.com 在 5 月 9 日星期四的一份报告中，将 EyePoint Pharmaceuticals 的评级从 “持有” 降至 “卖出”。一位投资分析师对该股票进行了卖出评级，七位分析师为该公司给出了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标股价为 33.71 美元。</p>
<p><strong>查看我们对 EyePoint Pharmaceuticals 的最新股票分析</strong></p>
<h2>EyePoint Pharmaceuticals 股票表现</h2>
<p>该股票的 50 天移动平均股价为 16.50 美元，200 天移动平均股价为 19.82 美元。该公司的市值为 5.1455 亿美元，市盈率为-5.45，贝塔系数为 1.59。</p>
<p>EyePoint Pharmaceuticals（NASDAQ：EYPT）上次公布季度财报是在 5 月 8 日星期三。公司报告该季度每股收益（EPS）为（0.55）美元，低于分析师预期的（0.34）美元。EyePoint Pharmaceuticals 的净利润率为-157.77%，净资产收益率为-49.94%。该季度公司的营收为 1,168 万美元，低于分析师预期的 1,250 万美元。分析师预计 EyePoint Pharmaceuticals, Inc.今年将实现每股盈利-2.14 美元。</p>
<h2>内部交易活动</h2>
<p>据报道，董事 David R. Guyer 于 5 月 14 日星期二出售了 11,625 股 EyePoint Pharmaceuticals 股票。这些股票的平均售价为 12.65 美元，总交易额为 147,056.25 美元。交易完成后，该董事在公司中直接持有 5,550 股股票，价值约 70,207.50 美元。该交易已在美国证券交易委员会（SEC）的法律文件中披露，可通过此超链接查看。此外，董事 David R. Guyer 还于 5 月 14 日星期二另一次出售了 11,625 股 EyePoint Pharmaceuticals 股票。这些股票的平均售价为 12.65 美元，总交易额为 147,056.25 美元。交易完成后，该董事在公司中直接持有 5,550 股股票，价值约 70,207.50 美元。该交易已在美国证券交易委员会（SEC）的法律文件中披露，可在 SEC 网站上找到。此外，主要股东 Cormorant Asset Management, Lp 于 5 月 6 日星期一以每股 11.86 美元的平均价格收购了该公司的 850,000 股股票，总价值为 10,081,000.00 美元。交易完成后，该内部人士在公司中直接持有 8,325,000 股股票，价值 98,734,500 美元。有关此次购买的披露可在此处找到。内部人士持有该公司的股份的比例为 4.74%。</p>
<h2>EyePoint Pharmaceuticals 的机构交易</h2>
<p>对冲基金和其他机构投资者最近已买入和卖出了该公司的股票。FNY Investment Advisers LLC 在第四季度购入了 EyePoint Pharmaceuticals 的新股份，价值约 27,000 美元。Ameritas Investment Partners Inc.在第一季度将其对 EyePoint Pharmaceuticals 的持股增加了 44.0%，现在拥有 3,719 股该公司股票，价值 77,000 美元，较之前增加了 1,136 股。China Universal Asset Management Co. Ltd.在第四季度购入了 EyePoint Pharmaceuticals 的新股份，价值 94,000 美元。Sherbrooke Park Advisers LLC 在第三季度购入了 EyePoint Pharmaceuticals 的新股份，价值 101,000 美元。最后，Tower Research Capital LLC TRC 在第四季度将其对 EyePoint Pharmaceuticals 的持股增加了 36.0%，现在拥有 4,724 股该公司股票，价值 109,000 美元，较之前增加了 1,250 股。99.41% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>关于 EyePoint Pharmaceuticals（获取免费报告）</h2>
<p>EyePoint Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，致力于开发和商业化治疗严重视网膜疾病患者生活的药物。该公司的产品线利用其专有的可生物降解的 Durasert E 技术，用于持续眼内药物释放。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 EyePoint Pharmaceuticals 更好</li>
<li>在购买股票之前如何评估一家公司</li>
<li>为什么 Smartsheet 股票是被低估的投资宝石</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Q1 季度财报后最受推崇的股票</li>
<li>技术指标如何帮助您找到被超卖的股票</li>
<li>什么是风险承受能力，为什么它很重要？</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 必看：埃隆的新发明绝对疯狂（来自 InvestorPlace）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3"/></p>
<h2>现在是否值得投资 EyePoint Pharmaceuticals $1,000？</h2>
<p>在考虑投资 EyePoint Pharmaceuticals 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该买入的股票...而 EyePoint Pharmaceuticals 并不在名单上。</p>
<p>虽然 EyePoint Pharmaceuticals 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

纳斯达克 OMX 交易所

EYPT

<p>眼点制药（NASDAQ：EYPT）股票在午间交易中下跌了 6.4%，交易量也有所下降。分析师已经调低了该股的价格目标，公司最近的财报显示净利润率为负。内部人士的交易活动包括一位董事出售股份和一位主要股东增持股份。对冲基金和机构投资者也一直在买卖股份。该股票的 50 天移动平均价为 16.50 美元</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA" alt="" original-src="https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png?v=20221222155024"/></p>
<p>Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) dropped 6.4% during mid-day trading on Monday . The stock traded as low as $9.96 and last traded at $10.02. Approximately 436,621 shares were traded during trading, a decline of 60% from the average daily volume of 1,101,198 shares. The stock had previously closed at $10.71.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.（NASDAQ：EYPT）股票在周一的午盘交易中下跌了 6.4%。股价最低跌至 9.96 美元，最后交易价为 10.02 美元。交易中约有 436,621 股股票交易，较平均日交易量 1,101,198 股下降了 60%。该股票上一个收盘价为 10.71 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>EYPT has been the topic of several research reports. Chardan Capital dropped their price objective on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Robert W. Baird lowered their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, May 8th. Capital One Financial reissued an &#34;overweight&#34; rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Mizuho lowered their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Finally, StockNews.com lowered EyePoint Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $33.71.</p>
<div class="lb-trans"><p>EYPT 已成为多份研究报告的主题。Chardan Capital 将 EyePoint Pharmaceuticals 的目标股价从 39.00 美元降至 28.00 美元，并在 5 月 7 日星期二的一份报告中为该股票设定了 “买入” 评级。Robert W. Baird 将 EyePoint Pharmaceuticals 的目标股价从 46.00 美元降至 38.00 美元，并在 5 月 8 日星期三的一份报告中为该股票设定了 “表现优异” 评级。Capital One Financial 在 2 月 16 日星期五的一份报告中重申了对 EyePoint Pharmaceuticals 股票的 “超重” 评级。Mizuho 将 EyePoint Pharmaceuticals 的目标股价从 39.00 美元降至 30.00 美元，并在 5 月 7 日星期二的一份报告中为该股票设定了 “买入” 评级。最后，StockNews.com 在 5 月 9 日星期四的一份报告中，将 EyePoint Pharmaceuticals 的评级从 “持有” 降至 “卖出”。一位投资分析师对该股票进行了卖出评级，七位分析师为该公司给出了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标股价为 33.71 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on EyePoint Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 EyePoint Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>EyePoint Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>EyePoint Pharmaceuticals 股票表现</h2>
</div><p>The stock's 50-day moving average price is $16.50 and its 200-day moving average price is $19.82. The company has a market capitalization of $514.55 million, a price-to-earnings ratio of -5.45 and a beta of 1.59.</p>
<div class="lb-trans"><p>该股票的 50 天移动平均股价为 16.50 美元，200 天移动平均股价为 19.82 美元。该公司的市值为 5.1455 亿美元，市盈率为-5.45，贝塔系数为 1.59。</p>
</div><p>EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.21). EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative return on equity of 49.94%. The company had revenue of $11.68 million for the quarter, compared to analyst estimates of $12.50 million. Analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals（NASDAQ：EYPT）上次公布季度财报是在 5 月 8 日星期三。公司报告该季度每股收益（EPS）为（0.55）美元，低于分析师预期的（0.34）美元。EyePoint Pharmaceuticals 的净利润率为-157.77%，净资产收益率为-49.94%。该季度公司的营收为 1,168 万美元，低于分析师预期的 1,250 万美元。分析师预计 EyePoint Pharmaceuticals, Inc.今年将实现每股盈利-2.14 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the sale, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the transaction, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the business's stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $11.86 per share, with a total value of $10,081,000.00. Following the completion of the transaction, the insider now directly owns 8,325,000 shares in the company, valued at $98,734,500. The disclosure for this purchase can be found here. Insiders own 4.74% of the company's stock.</p>
<div class="lb-trans"><p>据报道，董事 David R. Guyer 于 5 月 14 日星期二出售了 11,625 股 EyePoint Pharmaceuticals 股票。这些股票的平均售价为 12.65 美元，总交易额为 147,056.25 美元。交易完成后，该董事在公司中直接持有 5,550 股股票，价值约 70,207.50 美元。该交易已在美国证券交易委员会（SEC）的法律文件中披露，可通过此超链接查看。此外，董事 David R. Guyer 还于 5 月 14 日星期二另一次出售了 11,625 股 EyePoint Pharmaceuticals 股票。这些股票的平均售价为 12.65 美元，总交易额为 147,056.25 美元。交易完成后，该董事在公司中直接持有 5,550 股股票，价值约 70,207.50 美元。该交易已在美国证券交易委员会（SEC）的法律文件中披露，可在 SEC 网站上找到。此外，主要股东 Cormorant Asset Management, Lp 于 5 月 6 日星期一以每股 11.86 美元的平均价格收购了该公司的 850,000 股股票，总价值为 10,081,000.00 美元。交易完成后，该内部人士在公司中直接持有 8,325,000 股股票，价值 98,734,500 美元。有关此次购买的披露可在此处找到。内部人士持有该公司的股份的比例为 4.74%。</p>
</div><h2>Institutional Trading of EyePoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>EyePoint Pharmaceuticals 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in EyePoint Pharmaceuticals in the 4th quarter worth approximately $27,000. Ameritas Investment Partners Inc. grew its stake in shares of EyePoint Pharmaceuticals by 44.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock valued at $77,000 after buying an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter valued at $94,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at $101,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of EyePoint Pharmaceuticals by 36.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company's stock valued at $109,000 after buying an additional 1,250 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近已买入和卖出了该公司的股票。FNY Investment Advisers LLC 在第四季度购入了 EyePoint Pharmaceuticals 的新股份，价值约 27,000 美元。Ameritas Investment Partners Inc.在第一季度将其对 EyePoint Pharmaceuticals 的持股增加了 44.0%，现在拥有 3,719 股该公司股票，价值 77,000 美元，较之前增加了 1,136 股。China Universal Asset Management Co. Ltd.在第四季度购入了 EyePoint Pharmaceuticals 的新股份，价值 94,000 美元。Sherbrooke Park Advisers LLC 在第三季度购入了 EyePoint Pharmaceuticals 的新股份，价值 101,000 美元。最后，Tower Research Capital LLC TRC 在第四季度将其对 EyePoint Pharmaceuticals 的持股增加了 36.0%，现在拥有 4,724 股该公司股票，价值 109,000 美元，较之前增加了 1,250 股。99.41% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>About EyePoint Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 EyePoint Pharmaceuticals（获取免费报告）</h2>
</div><p>EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，致力于开发和商业化治疗严重视网膜疾病患者生活的药物。该公司的产品线利用其专有的可生物降解的 Durasert E 技术，用于持续眼内药物释放。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than EyePoint Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Why Smartsheet Stock is an Undervalued Gem of an Investment</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>The Most Upgraded Stocks After the Q1 Earnings Season</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>What Is Risk Tolerance &amp; Why Is It Important?</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五只股票，比 EyePoint Pharmaceuticals 更好</li>
<li>在购买股票之前如何评估一家公司</li>
<li>为什么 Smartsheet 股票是被低估的投资宝石</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Q1 季度财报后最受推崇的股票</li>
<li>技术指标如何帮助您找到被超卖的股票</li>
<li>什么是风险承受能力，为什么它很重要？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 必看：埃隆的新发明绝对疯狂（来自 InvestorPlace）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8087&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in EyePoint Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 EyePoint Pharmaceuticals $1,000？</h2>
</div><p>Before you consider EyePoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 EyePoint Pharmaceuticals 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该买入的股票...而 EyePoint Pharmaceuticals 并不在名单上。</p>
</div><p>While EyePoint Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 EyePoint Pharmaceuticals 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

EyePoint Pharmaceuticals（纳斯达克：EYPT）股价下跌 6.4%